Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT03925662
Recruiting Phase 3

Mebendazole as Adjuvant Treatment for Colon Cancer

NCT03925662 · tracked via the Priya Life Science Egypt tracker
Sponsor
Sherief Abd-Elsalam
Phase
Phase 3
Started
2019-04-01
Last updated
2019-04-24

Condition(s) studied

Colorectal Cancer

Investigational drug(s) / intervention(s)

Folfox with avastin →Mebendazole →

Folfox with avastin: Folfox with avastin only

Mebendazole: Folfox with avastin with mebendazole

Study summary

mebendazole treating colon cancer

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Colorectal cancer stage 4. Exclusion Criteria: * Agranulocytosis * Pregnancy * Allergy to mebendazole.

Primary outcome measure(s)

  • number of patients with tumour response — 6 months
    number of patients with response

Trial sites (1)

FacilityCityRegionStatus
Sherief Abd-Elsalam Cairo Egypt Recruiting

More Sherief Abd-Elsalam trials in Egypt

Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics Recruiting
Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis Recruiting
Docosahexaenoic Acid on Breath Holding Spells in Children Recruiting
Utility of Some Novel Biomarkers of Patients With Chronic Heart Failure Recruiting
Role of Coenzyme Q in ADHD in Children Recruiting

Other trials for the same condition

Qigong Exercise for Muscles Strength and Quality of Life in Colorectal Cancer Patients Undergoing Chemotherapy Starting soon
Dose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen Active, not recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer Recruiting
Nurse-Led Prehabilitation Before Major Abdominal Cancer Surgery Starting soon
Anastomotic Leakage After Colorectal Surgery. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03925662 on ClinicalTrials.gov ↗ ← All trials in Egypt